Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.

ABSTRACT: Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label, proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and quercetin (Q), was conducted in early-stage symptomatic patients with AD to assess central nervous system (CNS) penetrance, safety, feasibility and efficacy. Five participants (mean age = 76 + 5 years; 40% female) completed the 12-week pilot study. D and Q levels in blood increased in all participants (12.7-73.5 ng ml^-1 for D and 3.29-26.3 ng ml^-1 for Q). In cerebrospinal fluid (CSF), D levels were detected in four participants (80%) ranging from 0.281 to 0.536 ml^-1 with a CSF to plasma ratio of 0.422-0.919%; Q was not detected. The treatment was well-tolerated, with no ear

SUBMITTER: Gonzales MM 

PROVIDER: S-EPMC10875739 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature